A significant reduction in severe COPD exacerbations was seen with intensified combination therapy at the onset of upper respiratory tract infections.
Patients with type 2 diabetes treated with sulfonylureas had a higher risk of contracting tuberculosis compared with metformin.
Patients with COPD may increase their physical activity levels using a home-based coaching intervention.
Patients with stable hypercapnic COPD reported improved health-related quality of life after 6 weeks of at-home high-flow nasal cannula oxygen therapy.
Mortality from severe pneumonia may be significantly reduced with corticosteroids.
Within the first 30 days of therapy, patients with COPD who began using long-acting bronchodilators had a 1.5-fold increased risk for cardiovascular events.
Researchers from the National Institute of Allergy and Infectious Diseases are working to develop a universal influenza vaccine.
AuroMedics Pharma announced a voluntary recall of 1 lot of Linezolid injection after a batch found contained mold.
Bosentan may benefit a subset of patients with idiopathic pulmonary fibrosis-associated pulmonary hypertension.
A clinical trial is underway to assess the safety and efficacy of dabigatran in intermediate-risk pulmonary embolism after completing 72 hours of heparin therapy.
New recommendations suggest that high risk tuberculosis patients with cough should be screened for pulmonary tuberculosis.
Asthma exacerbations may be reduced in patients with eosinophilic asthma treated with benralizumab.
Carvedilol may increase the risk for hospitalization in patients with concurrent heart failure and COPD compared with metoprolol/bisoprolol/nebivolol.
Platinum-based chemotherapy agents for lung cancer may increase the risk for thromboembolism.
Patients with an egg allergy do not need to avoid or take special precautions when receiving the influenza vaccine.
The FDA announced a new enforcement strategy to regulate drug products labeled as homeopathic.
Broad-spectrum antibiotics are not associated with better clinical or patient-centered outcomes in children with acute respiratory tract infections.
In patients with acute respiratory distress syndrome, cisatracurium does not improve mortality when compared with vecuronium, but is associated with improvements in other outcomes.
Updates were also made to the Warnings and Precautions section of labeling for ICS/LABA-class medications.
At a research seminar held by the European Respiratory Society in February 2017, a group of investigators discussed how precision medicine may improve treatment in asthma and COPD.